Slingluff CL - Search Results

1

Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4⁺ and CD8⁺ T cells for immunotherapy of cancer.

Melssen MM, Fisher CT, Slingluff CL, Melief CJM. Melssen MM, et al. Among authors: slingluff cl. J Immunother Cancer. 2022 Sep;10(9):e004709. doi: 10.1136/jitc-2022-004709. J Immunother Cancer. 2022. PMID: 36939214 Free PMC article. Review.

2

Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms.

Slingluff CL. Slingluff CL. Cancer Immunol Immunother. 1999 Oct;48(7):371-3. doi: 10.1007/s002620050588. Cancer Immunol Immunother. 1999. PMID: 10501849 Free PMC article. Review.

3

Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

Slingluff CL Jr, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG. Slingluff CL Jr, et al. Clin Cancer Res. 2001 Oct;7(10):3012-24. Clin Cancer Res. 2001. PMID: 11595689 Clinical Trial.

4

Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine.

Woodson EM, Chianese-Bullock KA, Wiernasz CJ, Bissonette EA, Grosh WW, Neese PY, Merrill PK, Barnd DL, Petroni GR, Slingluff CL Jr. Woodson EM, et al. Among authors: slingluff cl jr. J Immunother. 2004 Sep-Oct;27(5):380-8. doi: 10.1097/00002371-200409000-00006. J Immunother. 2004. PMID: 15314546 Clinical Trial.

5

CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease.

Mullins IM, Slingluff CL, Lee JK, Garbee CF, Shu J, Anderson SG, Mayer ME, Knaus WA, Mullins DW. Mullins IM, et al. Among authors: slingluff cl. Cancer Res. 2004 Nov 1;64(21):7697-701. doi: 10.1158/0008-5472.CAN-04-2059. Cancer Res. 2004. PMID: 15520172

6

Competition among peptides in melanoma vaccines for binding to MHC molecules.

Thompson LW, Garbee CF, Hibbitts S, Brinckerhoff LH, Pierce RA, Chianese-Bullock KA, Deacon DH, Engelhard VH, Slingluff CL Jr. Thompson LW, et al. Among authors: slingluff cl jr. J Immunother. 2004 Nov-Dec;27(6):425-31. doi: 10.1097/00002371-200411000-00002. J Immunother. 2004. PMID: 15534486

7

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.

Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, Patterson JW, Fink R, Rehm PK. Slingluff CL Jr, et al. Clin Cancer Res. 2007 Nov 1;13(21):6386-95. doi: 10.1158/1078-0432.CCR-07-0486. Clin Cancer Res. 2007. PMID: 17975151 Clinical Trial.

8

Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2.

Molhoek KR, McSkimming CC, Olson WC, Brautigan DL, Slingluff CL Jr. Molhoek KR, et al. Among authors: slingluff cl jr. Cancer Immunol Immunother. 2009 Jun;58(6):867-76. doi: 10.1007/s00262-008-0602-6. Epub 2008 Oct 8. Cancer Immunol Immunother. 2009. PMID: 18841360 Free PMC article.

9

Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.

Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA. Slingluff CL Jr, et al. Clin Cancer Res. 2009 Nov 15;15(22):7036-44. doi: 10.1158/1078-0432.CCR-09-1544. Epub 2009 Nov 10. Clin Cancer Res. 2009. PMID: 19903780 Free PMC article. Clinical Trial.

10

Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.

Slingluff CL, Petroni GR, Smolkin ME, Chianese-Bullock KA, Smith K, Murphy C, Galeassi N, Neese PY, Grosh WW, Nail CJ, Ross M, von Mehren M, Haas N, Boisvert ME, Kirkwood JM. Slingluff CL, et al. J Immunother. 2010 Jul-Aug;33(6):630-8. doi: 10.1097/CJI.0b013e3181e311ac. J Immunother. 2010. PMID: 20551833 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

268 results

Search Page